HCW Biologics vs Roivant Sciences
HCWB and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCWB and ROIV compare
Roivant Sciences is the larger company, worth 19604 times as much as HCW Biologics ($28.0B against $1.4M).
HCW Biologics grew revenue faster over the last twelve months (700% versus −67.6% for Roivant Sciences).
HCW Biologics keeps more of each dollar of sales as profit, with a net margin of −83.8% compared with −3535% at Roivant Sciences.
Roivant Sciences scores higher on the StockData Score (7 against 6 for HCW Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCWB | ROIV |
|---|---|---|
| Size and price | ||
| Market cap | $1.4M | $28.0B |
| Share price | $0.777 | $38.71 |
| Change, 1 year | −95.7% | 90.8% |
| Change, 5 years | −99.9% | 453% |
| Beta (5Y) | 2.48 | 0.42 |
| Employees | – | 721 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× (better) | 3712× |
| P/B | 0.2× (better) | 6.6× |
| FCF yield | – | −2.9% |
| Fair value | $15.10 | – |
| Margin of safety | 94.9% | – |
| Growth | ||
| Revenue growth (TTM) | 700% (better) | −67.6% |
| Revenue growth, 5Y average | −57.9% | −19.1% (better) |
| Profitability | ||
| Gross margin | 96.7% | – |
| Operating margin | −115% (better) | −7915% |
| Net margin | −83.8% (better) | −3535% |
| FCF margin | – | −10901% |
| Return on equity | −151% | −6.2% (better) |
| Return on invested capital | −70.7% (better) | −407% |
| Financial health | ||
| Debt / equity | 0.88 (better) | 0.00 |
| Interest coverage | −14.0× | – |
| Current ratio | 0.06 | 16.72 (better) |
| Altman Z-score | −7.21 | 44.02 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 5.6% | 78.1% |
| Held by insiders | 34.9% | 13.9% |
| Insider net buying, 12 months | $532K (better) | −$798M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.1% | 7.3% |
Go deeper
- HCWB stock overview
- HCWB income statement
- HCWB valuation and score
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.